Michael Krams, M.D., Joins Exscientia as Chief Quantitative Medicine Officer
5.4.2022 15:00:00 EEST | Business Wire | Press release
Exscientia plc (Nasdaq: EXAI) today announced the appointment of Michael Krams, M.D., as its Chief Quantitative Medicine Officer. In this newly created role, Dr. Krams will lead clinical development strategy for Exscientia’s portfolio of investigational medicines. Exscientia’s drug discovery platform utilises patient-based translational models and AI-driven molecule design to optimise drug candidates for specific patient populations. As part of these efforts, Dr. Krams will drive work to improve trial design and patient selection within clinical trials to maximise clinical success and patient benefit.
“We want to be as innovative in the clinic as we have been in drug discovery. Mike is a proven innovator and strategic leader at the vanguard of bringing a quantitative science approach to clinical development. He has been a thought leader in the field for more than 20 years, implementing model-informed drug development, increasing the use of biomarkers to enable adaptive trials, and finding better ways to enrich trials for patient selection,” said Andrew Hopkins, DPhil., Exscientia’s founder and CEO. “Focusing our clinical trials on the people that are most likely to benefit from them has the potential to not only improve clinical success rates, but it also advances our mission of putting patients at the centre of creating new medicines.”
Dr. Krams joins Exscientia’s executive leadership team, reporting to Andrew Hopkins, and will be based at Exscientia’s precision medicine centre in Vienna, Austria. Dr. Krams most recently led the Quantitative Sciences group at Janssen R&D, bringing together approximately 500 statisticians, pharmacologists and modellers to enable efficient decision-making in various aspects of drug development. Earlier in his career, he was Vice President of Adaptive Trials and Applied Program Strategies at Wyeth. Dr. Krams holds an M.D. from the University of Munich.
“I’m pleased to join Exscientia, a mission-driven company harnessing artificial intelligence to transform drug discovery and development to make better medicines for patients. In many ways, the work I’ve driven throughout my career is a good match to Exscientia’s goal - asking how conventional, sequential approaches to clinical development can be further improved, aiming for truly patient-driven medicine development. Discovery and clinical strategies need to be closely connected through biomarker strategies and Exscientia’s precision medicine platform has the potential to achieve just that,” said Mike Krams, M.D., Chief Quantitative Medicine Officer for Exscientia.
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 30 projects underway. By designing better drugs, faster, we believe the best ideas of science can rapidly become the best medicines for patients.
Exscientia is headquartered in Oxford (England, U.K.), with offices in Vienna (Austria), Dundee (Scotland, U.K.), Boston (Mass., U.S.), Miami (Fla., U.S.), Cambridge (England, U.K.), and Osaka (Japan).
Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements with regard to Exscientia’s expectations regarding its management team. Words such as “anticipates,” "believes," “expects,” "intends," "projects," "anticipates," and "future" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the uncertainties inherent in predicting future results and conditions and no assurance can be given that the drug discovery and precision medicine platforms discussed above will be successful in optimising drug candidates for specific patient populations. The success of Exscientia’s platforms is subject to numerous factors, many of which are beyond the control of Exscientia, including, without limitation, the ability of Exscientia to design clinical trials that are cleared by the FDA and of healthcare providers to collect viable patient tissue samples. Exscientia undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005276/en/
Contact information
Investors:
Sara Sherman
investors@exscientia.ai
Media:
Amanda Galgay
media@exscientia.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pioneering feat in regenerative medicine, the BEES-HAUS cell therapy: Paracrine effect and cell engraftment, together healing urethral stricture. Its simplified version, BHES-HAUS’ results to be presented in AUA 20267.5.2026 08:13:00 EEST | Press release
A path breaking scientific discovery, unraveling successful wound healing mechanism in urethral stricture with BEES-HAUS cell therapy has been reported by Indo-Japan physician-scientists. This milestone achievement in regenerative medicine, yielding clinical safety and efficacy, is the first of its kind, wherein a hybrid approach of mixing two groups of autologous buccal epithelial cells,one cultured in 2D and another in 3D in Festigel scaffold were used in the management of urethral stricture; paracrine effect of IGF-1 produced by 2D-cultured cells and engraftment of 3D-Festigel cultured cells, which cover the urethrotomy wound, together repairing the urothelial defect, has been published in Frontiers in Urology. This feat though modest, is a global first in terms of both in vitro tissue engineering and clinical benefits by in vivo healing, restoring the urothelial integrity and is a giant leap for its potential of yielding stricture recurrence-free good quality of life to patients wi
Interactive Brokers Launches Access to Korean Equities, Breaking New Ground for Global Investors7.5.2026 04:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of access to equities listed on the Korea Exchange (KRX), becoming the first major US-based broker to offer seamless trading in Korea's $1.8 trillion equity market. Korea ranks fourth among Asia's equity markets and tenth globally by market capitalization, with over $10 billion in daily volume – liquidity comparable to many European exchanges. The market is home to category-leading semiconductor manufacturers, automotive innovators, and consumer technology companies with global footprints, including Samsung Electronics, SK Hynix, and Hyundai Motor. As one of Asia’s most liquid markets, Korea represents a point of entry for international investors seeking exposure to the region’s technology leadership and industrial innovation. For investors operating across multiple markets and time zones, Interactive Brokers' launch expands the ability to build truly global portfolios with the same integrated tr
Brightfin Launches Spend Clearly AI to Help Enterprise Tech Leaders Take Control of Growing IT and AI Costs6.5.2026 23:32:00 EEST | Press release
Brightfin, a leader in AI native IT cost optimization, today announced the launch of Spend Clearly AI, an intelligent optimization app purpose-built for enterprise technology leaders navigating the dual pressures of rising IT complexity and rapidly escalating AI investment. As organizations race to deploy AI apps, models, and infrastructure, technology demands on the budget are expanding faster than ever and growing harder to track, justify, and control. The modern enterprise IT bill has become a moving target. Spend Clearly AI gives CIOs, CTOs, and IT finance teams a single, intelligent app to see exactly where every technology dollar is going, eliminate waste, and stay ahead of costs before they spiral. "Stop thinking about IT as a cost problem. The goal isn't just to spend less — the goal is to spend better," said Joel Martins, CEO of Brightfin. "When you have real visibility and can trace every technology dollar to what it's delivering, you stop cutting and start optimizing. CIOs w
iQmetrix to Showcase Intelligent Commerce Operating System and Catalyst Innovation at DTW Ignite 20266.5.2026 20:20:00 EEST | Press release
iQmetrix, the Intelligent Commerce Operating System for telecom, announced today it will exhibit, speak, and compete as a bronze sponsor at DTW Ignite 2026 in Copenhagen from June 23–25. The company will deliver a live product demo in The Loft, showcase its ODA PRISM Catalyst project alongside a consortium of global operators and technology partners, and exhibit at Booth #317 throughout the event. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506948390/en/ The debut marks a milestone in iQmetrix’s global growth strategy and deepens its partnership with TM Forum, following its recent recognition as an ODA Component Directory Partner. The Future of Commerce Is Won at the Orchestration Layer DTW Ignite 2026’s theme, “The Future. Faster.,” captures the urgency facing communications service providers worldwide. Telcos have spent decades building world-class networks that consumers increasingly take for granted, yet that inves
Go Beyond the Guidebook: Why Ireland Rewards Those Who Slow Down6.5.2026 19:15:00 EEST | Press release
In a world where travel often feels rushed and driven by checklists, Ireland stands apart. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501313521/en/ Lusty Beg Island Kesh, Co. Fermanagh The destination offers something deeper, drawing visitors beyond the expected toward richer encounters with its landscapes, culture and communities. As a compact island, Ireland gives holiday makers the chance to take in much of the destination while still travelling at a relaxed, unhurried pace. It’s a chance to slow down, not to do less, but to feel more - more calm, more connection, and more of what makes travel meaningful. This approach to travel is matched by Ireland’s natural warmth and welcome, helping visitors feel at home from the moment they arrive. Take the scenic route From the rugged coastline of the Wild Atlantic Way, one of the world’s longest coastal routes, to the rolling landscapes of Ireland’s Hidden Heartlands, Irela
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom